ACADIA Pharmaceuticals (ACAD) Resumen de Acciones
ACADIA Pharmaceuticals Inc, empresa biofarmacéutica, centra su actividad en el desarrollo y la comercialización de medicamentos para enfermedades neurológicas y raras en Norteamérica. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 4/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
ACAD Community Fair Values
Create NarrativeSee what 103 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$28.75
FV
9.7% infravalorado descuento intrínseco10.02%
Revenue growth p.a.
41
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Competidores de ACADIA Pharmaceuticals Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$25.97 |
| Máximo en las últimas 52 semanas | US$28.35 |
| Mínimo de 52 semanas | US$19.69 |
| Beta | 0.80 |
| Cambio en 1 mes | 20.45% |
| Variación en 3 meses | 16.35% |
| Cambio de 1 año | 23.96% |
| Variación en 3 años | 6.43% |
| Variación en 5 años | 9.53% |
| Variación desde la OPV | 287.61% |
Noticias y actualizaciones recientes
Seeking Alpha • Jun 29
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus
Summary Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europe. Remlifanserin's upcoming phase 2 readout in Alzheimer's disease psychosis is a high-risk, high-reward catalyst not priced into ACAD's current valuation. I maintain a bullish outlook on ACAD based on commercial products Nuplazid and Daybue, but above-average returns depend on pipeline or business development success. ACAD's valuation remains below the combined Nuplazid and Daybue value, with $851M cash and positive cash flows supporting future pipeline expansion. Read the full article on Seeking Alpha
Actualización de narrativa • Jun 17
ACAD: Buy Upgrade And Guidance Reaffirmation Will Drive Upside From Pullback
ACADIA Pharmaceuticals' analyst price target has been trimmed by $1, as analysts recalibrate their models around slightly different long term growth, profitability, and discount rate assumptions reflected in recent research updates. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals shows a mix of caution and optimism, with the modest price target trim sitting alongside more constructive views from bullish analysts who see room for the stock to recover from recent weakness.Recent updates
Seeking Alpha • Jun 29
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus
Summary Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europe. Remlifanserin's upcoming phase 2 readout in Alzheimer's disease psychosis is a high-risk, high-reward catalyst not priced into ACAD's current valuation. I maintain a bullish outlook on ACAD based on commercial products Nuplazid and Daybue, but above-average returns depend on pipeline or business development success. ACAD's valuation remains below the combined Nuplazid and Daybue value, with $851M cash and positive cash flows supporting future pipeline expansion. Read the full article on Seeking AlphaActualización de narrativa • Jun 17
ACAD: Buy Upgrade And Guidance Reaffirmation Will Drive Upside From Pullback
ACADIA Pharmaceuticals' analyst price target has been trimmed by $1, as analysts recalibrate their models around slightly different long term growth, profitability, and discount rate assumptions reflected in recent research updates. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals shows a mix of caution and optimism, with the modest price target trim sitting alongside more constructive views from bullish analysts who see room for the stock to recover from recent weakness.
Actualización de narrativa • Jun 02
ACAD: Rett And Alzheimer’s Psychosis Milestones Will Shape Balanced Risk Reward
Analysts have nudged their price expectations for ACADIA Pharmaceuticals higher, with the updated fair value estimate moving from about $19.64 to $19.75 per share as they refine assumptions around growth, margins, and future P/E multiples following recent target changes and rating updates on the stock. Analyst Commentary Recent Street research on ACADIA Pharmaceuticals reflects a mix of optimism and caution, with some firms lifting price targets and others trimming expectations or flagging risks.Actualización de narrativa • May 09
ACAD: Remlifanserin Alzheimer’s Psychosis Readout Will Drive Upside From Undervalued Levels
Analysts recently adjusted their fair value estimate for ACADIA Pharmaceuticals slightly lower to $43.55 from $43.97, reflecting updated assumptions for revenue growth, profitability, and future P/E. This revision also incorporates mixed but generally constructive Street price target updates in the $26 to $37 range, along with several fresh Buy and Outperform ratings.Actualización de narrativa • Apr 23
ACAD: Execution Risk Around Rett Syndrome Setback Will Limit Future Upside
Analysts trimmed the fair value estimate for ACADIA Pharmaceuticals slightly to $19.64 from $19.73, as modestly higher discount rate assumptions offset slightly stronger projected revenue growth and profitability. They maintained a supportive stance following a mix of recent price target increases and reductions across the Street.
Actualización de narrativa • Apr 08
ACAD: Future Upside Will Depend On Alzheimer Psychosis Trial Outcomes
The fair value estimate for ACADIA Pharmaceuticals has increased slightly to $31.80, as analysts incorporate updated revenue growth assumptions, mixed adjustments to price targets across firms, and ongoing expectations for contributions from Nuplazid, Daybue, and the broader pipeline. Analyst Commentary Recent research coverage on ACADIA Pharmaceuticals shows a mix of optimism and caution, with several firms revising price targets after earnings updates, guidance, and pipeline commentary.Actualización de narrativa • Mar 24
ACAD: Remlifanserin Alzheimer’s Psychosis Data Will Drive Upside From Undervalued Levels
ACADIA Pharmaceuticals' updated analyst price target moves from $37 to about $44, with analysts pointing to refreshed models that reflect recent guidance, ongoing commercial momentum in Nuplazid and Daybue, and growing attention on the remlifanserin Phase 2 program in Alzheimer's disease psychosis. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals clusters around refreshed models, updated sales assumptions for Nuplazid and Daybue, and rising interest in the remlifanserin program in Alzheimer's disease psychosis.Actualización de narrativa • Mar 10
ACAD: Trofinetide EU Setback And Execution Risks Will Likely Restrain Upside
ACADIA Pharmaceuticals' updated analyst price target reflects a modest reset in fair value to $19.73 from $20.26, as analysts balance recent target revisions across the Street with refreshed assumptions for growth, margins, and future P/E levels. Analyst Commentary Across recent research updates, views on ACADIA are mixed, with several large firms expressing confidence in the commercial trajectory of Nuplazid and Daybue, while others are more measured and focused on execution risks and how much of the current pipeline is already reflected in the share price.Actualización de narrativa • Feb 23
ACAD: Pipeline And Execution Risks Will Likely Cap Upside Despite Renewed Optimism
ACADIA Pharmaceuticals' updated fair value estimate has edged up from $19.65 to $20.26 per share, reflecting analysts' higher price targets tied to confidence in Nuplazid and Daybue, as well as underappreciated upside from the remlifanserin pipeline asset. Analyst Commentary Recent research views on ACADIA are mixed, with some firms pointing to upside tied to Nuplazid, Daybue, and the remlifanserin program, while others are more guarded.Actualización de narrativa • Feb 09
ACAD: Higher P/E Assumptions Will Rely On Successful Rett Syndrome Expansion
Analysts have nudged their fair value estimate for ACADIA Pharmaceuticals higher by about $0.47 per share, reflecting recent price target revisions and updated assumptions around revenue growth, profitability, and future P/E multiples. Analyst Commentary Recent Street research on ACADIA Pharmaceuticals has been active, with multiple firms revising price targets and updating their views on the company.Actualización de narrativa • Jan 25
ACAD: Execution Risk And Sector Capital Pressures Will Likely Constrain Upside
Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing updated assumptions around revenue growth, profitability and future P/E expectations, alongside a generally cautious but constructive view on Biotech, with potential M&A activity helping to support the sector. Analyst Commentary While the updated US$40 target signals constructive sentiment on ACADIA Pharmaceuticals, recent commentary still carries a cautious tone around how the story plays out over time.Actualización de narrativa • Jan 11
ACAD: Higher P/E Assumptions Will Support Upside If Pipeline Milestones Deliver
Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing a refreshed view on fair value, updated discount rate assumptions, and adjusted expectations for revenue growth, profit margin, and future P/E multiples. Analyst Commentary Recent commentary around ACADIA Pharmaceuticals reflects a mix of optimism on potential value creation and caution around sector level capital trends.Actualización de narrativa • Dec 26
ACAD: Expanded Neuroscience Pipeline Will Drive Upside From Undervalued Levels
Analysts have modestly increased their price target on ACADIA Pharmaceuticals from 35.00 dollars to 37.00 dollars. They cited slightly stronger long term revenue growth, improved profit margin expectations, a marginally lower discount rate, and a higher projected future price to earnings multiple.Actualización de narrativa • Dec 12
ACAD: Upcoming Neuropsychiatric Data Expected To Drive Upside Despite Recent Setback
Analysts have trimmed their price target on ACADIA Pharmaceuticals by $5 to $35 per share. This reflects a modestly higher discount rate and lower long term profit expectations, despite slightly stronger projected revenue growth and reassurance that the ACP-101 failure has only a small impact on overall valuation.Artículo de análisis • Nov 13
Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings
Even though ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) posted strong earnings recently, the stock hasn't reacted in a...Artículo de análisis • Nov 09
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) came out with its quarterly results last week, and we wanted to see how the...Actualización de narrativa • Sep 26
Global Outreach And Pipeline Programs Will Expand CNS Markets
ACADIA Pharmaceuticals’ consensus price target was revised downward to $29.32 as the Phase 3 failure of ACP-101 in Prader-Willi syndrome modestly reduced pipeline value, though the impact is seen as limited given low expectations and resilience in the core business. Analyst Commentary Bearish analysts cite the Phase 3 failure of ACP-101 in Prader-Willi syndrome (PWS), which missed its primary endpoint, leading to lowered price targets based on reduced near-term pipeline value.Actualización de narrativa • Sep 04
Global Outreach And Pipeline Programs Will Expand CNS Markets
Analysts maintained their price target for ACADIA Pharmaceuticals at $29.95 as strong Daybue growth, favorable Nuplazid patent rulings, and strategic R&D focus offset near-term competitive and pipeline uncertainties. Analyst Commentary Bullish analysts are raising price targets citing strong Daybue growth in Q2, but note further acceleration is needed for material upside.Artículo de análisis • Aug 09
Results: ACADIA Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
NasdaqGS:ACAD 1 Year Share Price vs Fair Value Explore ACADIA Pharmaceuticals's Fair Values from the Community and...Artículo de análisis • May 30
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Surges 54% Yet Its Low P/S Is No Reason For Excitement
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shares have had a really impressive month, gaining 54% after a shaky period...Artículo de análisis • May 09
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) just released its first-quarter report and things are looking bullish...Artículo de análisis • Mar 03
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) last week reported its latest annual results, which makes it a good time...Seeking Alpha • Feb 13
Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy'
Summary Acadia Pharmaceuticals has shown significant financial improvement, reporting a profit of $82.7m in 2024, compared to a loss of $(107m) in 2023. The company's revenue growth is driven by NUPLAZID and DAYBUE, with 2024 revenue projections of $600m-$610m and $340m-$350m respectively, and overall revenues forecast to exceed $1bn in '25. Acadia's promising pipeline, including ACP-204 and ACP-101, and successful marketing campaigns suggest strong future growth potential. Given the company's profitability, robust pipeline, and undervaluation compared to peers, I am upgrading Acadia from "Sell" to "Buy". Read the full article on Seeking AlphaArtículo de análisis • Jan 08
Why Investors Shouldn't Be Surprised By ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 3.1x ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) is...Seeking Alpha • Nov 27
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
Summary NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is on track to reach more than $1 billion in annualized net product sales in 2025. Next phase of growth could come from two late-stage assets known as ACP-101 for hyperphagia of PWS and ACP-204 for Alzheimer's Disease Psychosis. Company entered into a worldwide license agreement with Saniona to develop and commercialize SAN711 for the treatment of patients with Essential Tremor; Phase 2 study to be initiated in 2026. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Summary Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also posted updated FY2024 guidance. Acadia Pharmaceuticals is becoming profitable, has a pristine balance sheet, and is seeing solid growth. An updated analysis around ACAD stock follows in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • Nov 08
ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shareholders, with its shares surging 18...
Nueva narrativa • Sep 09
Targeted Campaigns And Pipeline Expansions Set To Revolutionize Growth In Neurological Treatment Market
Targeted and DTC campaigns for NUPLAZID aimed at Parkinson's disease psychosis are expected to notably increase patient starts, directly enhancing market share and revenue.Seeking Alpha • Aug 26
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Summary Shares of Acadia trended lower this year due to Daybue's poor quarterly sales performance, and also due to Nuplazid's failure in the phase 3 trial in schizophrenia patients. The full-year guidance on Daybue was reduced as Acadia is finding fewer new patients, not because of higher patient churn. With most of the headwinds in the rearview mirror, I expect better performance of Daybue going forward. Nuplazid's strong performance remained largely unnoticed given the investor focus on Daybue. Other key pipeline projects are on track with ACP-204, and ACP-101 progressing in phase 2/3 and phase 3 trials, respectively. Read the full article on Seeking AlphaArtículo de análisis • Aug 14
The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Even though ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) posted strong earnings, investors appeared to be underwhelmed...Artículo de análisis • Aug 09
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) investors will be delighted, with the company turning in some strong...Artículo de análisis • Aug 01
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
ACADIA Pharmaceuticals Inc.'s ( NASDAQ:ACAD ) price-to-sales (or "P/S") ratio of 3.9x might make it look like a strong...Artículo de análisis • May 23
Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
Key Insights ACADIA Pharmaceuticals to hold its Annual General Meeting on 29th of May CEO Steve Davis' total...Rentabilidad de los accionistas
| ACAD | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 2.6% | 4.1% | 1.6% |
| 1Y | 24.0% | 41.1% | 18.6% |
Rentabilidad vs. Industria: Los resultados de ACAD fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 41.1% el año pasado.
Rentabilidad vs. Mercado: ACAD superó al mercado US, que obtuvo un rendimiento del 18.6% el año pasado.
Volatilidad de los precios
| ACAD volatility | |
|---|---|
| ACAD Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: ACAD no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ACAD (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1993 | 797 | Catherine Owen Adams | www.acadia.com |
ACADIA Pharmaceuticals Inc, empresa biofarmacéutica, se centra en el desarrollo y comercialización de medicamentos para enfermedades neurológicas y raras en Norteamérica. La compañía ofrece NUPLAZID (pimavanserin), un agonista/antagonista inverso selectivo de la serotonina para el tratamiento de las alucinaciones y delirios asociados con la psicosis de la enfermedad de Parkinson; y DAYBUE, un novedoso análogo sintético del tripéptido aminoterminal del factor de crecimiento 1 similar a la insulina para tratar los síntomas del síndrome de Rett reduciendo la neuroinflamación y apoyando la función sináptica. También desarrolla la remlifanserina, en fase 2 de ensayo clínico para el tratamiento de la psicosis de la enfermedad de Alzheimer y la demencia por cuerpos de Lewy; el ACP-211, en fase 2 de ensayo clínico para el tratamiento del trastorno depresivo mayor; el ACP-711, en fase I de ensayo clínico para el tratamiento del temblor esencial; y el ACP-271, un agonista del GPR88 para el tratamiento de la discinesia tardía y la enfermedad de Huntington, en fase I de ensayo.
Resumen de fundamentos de ACADIA Pharmaceuticals Inc.
| Estadísticas fundamentales de ACAD | |
|---|---|
| Capitalización bursátil | US$4.45b |
| Beneficios(TTM) | US$375.65m |
| Ingresos (TTM) | US$1.10b |
11.8x
Ratio precio-beneficio (PE)4.1x
Ratio precio-ventas (PS)¿Está ACAD sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ACAD | |
|---|---|
| Ingresos | US$1.10b |
| Coste de los ingresos | US$420.80m |
| Beneficio bruto | US$674.45m |
| Otros gastos | US$298.80m |
| Beneficios | US$375.65m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.19 |
| Margen bruto | 61.58% |
| Margen de beneficio neto | 34.30% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado ACAD a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/05 05:21 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
ACADIA Pharmaceuticals Inc. está cubierta por 37 analistas. 21 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Joel Beatty | Baird |
| null null | Baird |
| Jack Allen | Baird |